Schubert & CO Halozyme Therapeutics, Inc. Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$32.86 - $55.7 $2,037 - $3,453	-62 Reduced 64.58%	34 $1,000
Q4 2022 Jan 31, 2023	BUY	$40.06 - $59.44 $1,962 - $2,912	49 Added 104.26%	96 $5,000
Q3 2022 Oct 21, 2022	SELL	$38.53 - $51.78 $539 - $724	-14 Reduced 22.95%	47 $2,000
Q2 2022 Aug 01, 2022	BUY	$37.35 - $48.3 $1,606 - $2,076	43 Added 238.89%	61 $3,000
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $223 - $287	7 Added 63.64%	18 $1,000
Q4 2021 Jan 28, 2022	BUY	$31.82 - $40.75 $350 - $448	11 New	11 $0

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.